To evaluate the efficacy and safety of everolimus and sirolimus in patients with tuberous sclerosis complex-associated angiomyolipomas (TSC-AML).
There were high response rates in both two groups. With the prolonged medication time, the therapeutic efficacy of two agents became more significant. Everolimus had a more significant TSC-AML volume reduction after 6 and 12 months than sirolimus. More than 1/2 of everolimus patients had ≥ 50% reduction and approximately 80% of them had ≥ 30% reduction, higher than that of the sirolimus patients. Regarding safety, there was no significant difference in the incidence of AEs between the two groups.
Both everolimus and sirolimus are excellent therapeutic choices for TSC-AML. However, everolimus had a better therapeutic efficacy than sirolimus, especially in reducing TSC-AML volume. Therefore, everolimus is recommended as the first choice.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Posted 17 Mar, 2021
Received 07 Apr, 2021
On 07 Apr, 2021
Received 31 Mar, 2021
On 25 Mar, 2021
On 24 Mar, 2021
On 14 Mar, 2021
Received 14 Mar, 2021
Invitations sent on 11 Mar, 2021
On 11 Mar, 2021
On 11 Mar, 2021
On 11 Mar, 2021
On 06 Mar, 2021
Posted 17 Mar, 2021
Received 07 Apr, 2021
On 07 Apr, 2021
Received 31 Mar, 2021
On 25 Mar, 2021
On 24 Mar, 2021
On 14 Mar, 2021
Received 14 Mar, 2021
Invitations sent on 11 Mar, 2021
On 11 Mar, 2021
On 11 Mar, 2021
On 11 Mar, 2021
On 06 Mar, 2021
To evaluate the efficacy and safety of everolimus and sirolimus in patients with tuberous sclerosis complex-associated angiomyolipomas (TSC-AML).
There were high response rates in both two groups. With the prolonged medication time, the therapeutic efficacy of two agents became more significant. Everolimus had a more significant TSC-AML volume reduction after 6 and 12 months than sirolimus. More than 1/2 of everolimus patients had ≥ 50% reduction and approximately 80% of them had ≥ 30% reduction, higher than that of the sirolimus patients. Regarding safety, there was no significant difference in the incidence of AEs between the two groups.
Both everolimus and sirolimus are excellent therapeutic choices for TSC-AML. However, everolimus had a better therapeutic efficacy than sirolimus, especially in reducing TSC-AML volume. Therefore, everolimus is recommended as the first choice.
Figure 1
Figure 2
Loading...